FDA Approves VALPROATE SODIUM — Sagent Pharmaceuticals

# FDA Approves Sagent Pharmaceuticals' Intravenous Valproate Sodium Formulation Sagent Pharmaceuticals has received FDA approval for its intravenous formulation of valproate sodium (ANDA076295), expanding the company's portfolio in the anticonvulsant market and enabling broader clinical use for patients requiring parenteral administration. The approval positions Sagent to capture additional market share in the hospital and acute care settings where IV valproate therapy is indicated for seizure management.